Retatrutide

Last reviewed: 24 September 2026

Lazarus Labs supplies Retatrutide for laboratory and analytical research in Australia at ≥ 99 % purity, with published third-party laboratory reports. For research use only — not for human or veterinary use.

What is Retatrutide?

Research context

Retatrutide belongs to the incretin-mimetic class of research peptides, alongside compounds such as semaglutide and tirzepatide. Where those molecules act at one or two receptors, retatrutide is studied for its simultaneous activity across the GLP-1, GIP, and glucagon pathways — a mechanism laboratories examine in receptor-binding, signalling, and comparative metabolic studies. It is supplied strictly as a reference material for that work.

Specifications

• Available sizes: 10 mg and 20 mg vials
• Purity: ≥ 99 %, confirmed by HPLC and LC-MS
• Form: white lyophilised powder
• Solubility: readily soluble in water (H₂O)
• Manufacturing: GMP-compliant, ISO 9001:2008
• Documentation: published third-party laboratory reports
• Intended use: in-vitro and laboratory research only

Quality & documentation

Published Retatrutide reports record the tested sample’s identity, purity and batch reference. Match the batch printed on your vial to the original laboratory document; the published reports do not establish which batch will be dispatched. New to this compound? Our Retatrutide research overview covers the published literature and receptor pharmacology in more depth.

Handling & storage

Store sealed and dry at 2–8 °C. After reconstitution, keep prepared solution refrigerated and follow your laboratory’s own handling, stability, and disposal procedures. Retatrutide is supplied for research use only and is not for human or veterinary use.

Dispatch & supply in Australia

Retatrutide ships from within Australia with tracked delivery, so research groups receive material quickly and in appropriate packaging. Published reports can be viewed in the COA tab.

Read the citation-backed research overview →